Trending News

Webull (NASDAQ: BULL) reported strong Q1 2025 financial results, with total revenues growing 32% YoY to $117.4 million. The company achieved significant milestones including a 45% increase in customer assets to $12.6 billion and a 66% growth in net deposits. Trading metrics showed robust growth with equities notional volume up 15% to $128 billion and options contracts volume increasing 8% to 121 million. The company turned profitable with net income of $12.9 million, compared to a loss of $12.6 million in the previous year. Key operational metrics included a 17% increase in registered users to 24.1 million and 10% growth in funded accounts to 4.7 million. Notable developments included partnerships with Kalshi for binary trading, launch of Webull Premium subscription service, collaboration with BlackRock for model portfolios, and integration with Visa Direct for money transfers.

BloomZ (NASDAQ:BLMZ), a Japanese entertainment company specializing in VTuber and voice actor management, has announced a strategic business alliance with M-NEXT Holdings, owner of trading card retailer "Ryusei no Arashi". The partnership aims to create interactive customer experiences by combining BloomZ's VTuber and sound production expertise with M-NEXT's retail operations.

The collaboration includes: joint planning of experiential events and limited-edition products, monthly promotional campaigns featuring BloomZ's talent, and strategic support for Ryusei no Arashi's international expansion. The initiative will feature in-store event spaces designed like open-concept radio studios to host live, interactive events with BloomZ's VTubers and voice actors.

Iovance Biotherapeutics announced five-year results from the Phase 2 C-144-01 trial of Amtagvi® (lifileucel) in advanced melanoma patients. The study included 153 patients previously treated with anti-PD-1 and targeted therapy. Key findings with a median follow-up of 57.8 months include:

• 19.7% five-year survival rate with median overall survival of 13.9 months
• 31.4% objective response rate (5.9% complete responses, 25.5% partial responses)
• 36.5-month median duration of response
• 31.3% of responders maintained ongoing responses at five years

Amtagvi, approved by FDA in February 2024, is the first one-time T cell therapy for solid tumor cancer. The therapy demonstrated a favorable long-term safety profile with no new or late-onset treatment-related adverse events.

NextEra Energy (NYSE: NEE) has announced its regular quarterly dividend of $0.5665 per share, payable on June 16, 2025, to shareholders of record on June 2, 2025. The company, a Fortune 200 member, is one of North America's largest electric power and energy infrastructure companies, operating through its subsidiaries Florida Power & Light Company and NextEra Energy Resources. Florida Power & Light serves approximately 12 million customers across Florida, while NextEra Energy Resources focuses on energy infrastructure development with a diverse portfolio including natural gas, nuclear, renewable energy, and battery storage solutions.

PDS Biotech (NASDAQ: PDSB) announced significant extended follow-up data from its VERSATILE-002 trial and additional studies of Versamune® HPV to be presented at ASCO 2025. The VERSATILE-002 trial showed remarkable survival rates in HPV16-positive head and neck cancer patients: 39.3 months median overall survival for CPS ≥20 patients (vs ~15 months with pembrolizumab alone) and 30.0 months for CPS ≥1 patients (vs ~12 months with pembrolizumab). The ongoing Phase 3 VERSATILE-003 trial will enroll 351 patients to evaluate Versamune® HPV with pembrolizumab as first-line treatment. Additionally, a Phase 2 trial showed promising results with 70% stable disease rate using Versamune® HPV alone and 100% stable disease or partial response when combined with pembrolizumab in newly diagnosed patients.

Regeneron Pharmaceuticals (NASDAQ: REGN) announced promising initial results from their Phase 1b LINKER-MM2 trial evaluating linvoseltamab combinations with proteasome inhibitors for relapsed/refractory multiple myeloma. The study tested two combinations: 1. Linvoseltamab + Carfilzomib: - 90% objective response rate (19/21 patients) - 76% complete response rate - 87% probability of maintaining response at 12 months - 83% progression-free probability at 12 months 2. Linvoseltamab + Bortezomib: - 85% objective response rate (17/20 patients) - 50% complete response rate Both combinations showed manageable safety profiles, with neutropenia, cytokine release syndrome, and thrombocytopenia as common side effects. Linvoseltamab is already approved in the EU for R/R multiple myeloma, with FDA review expected by July 10, 2025.

Gemspring Capital Management has entered into a definitive agreement to acquire Goodyear's (NASDAQ: GT) polymer chemicals business. The acquisition includes two operating plants in Texas (Houston and Beaumont) and an R&D facility in Akron, Ohio. Goodyear Chemical, headquartered in Akron, is a leading North American synthetic rubber producer serving major tire manufacturers and various end markets including food, medical, sporting goods, and industrial applications.

Goodyear will retain its Chemical facilities in Niagara Falls, NY, and Bayport, TX. The transaction is expected to close by late 2025, subject to regulatory approval. Tesham Gor is expected to become CEO of the standalone business. Gemspring Capital, with $3.8 billion under management, aims to accelerate product development and expand customer relationships globally.

VCI Global (NASDAQ: VCIG) has announced a significant amendment to its equity line agreement with Alumni Capital LP. The key changes include:

The new agreement sets pricing for future equity issuances at 102% of the lowest trading price over the preceding five trading days, up from the previous 85%. This represents a substantial premium and improved terms for shareholders.

The company maintains discretionary access to a US$112 million facility, which can be utilized for strategic acquisitions, platform initiatives, or market opportunities. VCI Global, a diversified holding company focused on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy, views this revised agreement as a strategic tool to support its expansion while minimizing shareholder dilution.

Copart (NASDAQ: CPRT) has reported strong financial results for Q3 fiscal 2025. The company achieved quarterly revenue of $1.2 billion, representing a 7.5% increase year-over-year, while gross profit rose 5.1% to $552.3 million. Net income grew 6.4% to $406.6 million, with diluted EPS increasing 7.7% to $0.42.

For the nine-month period ending April 30, 2025, Copart posted even more robust growth with revenue up 11.2% to $3.5 billion, gross profit increasing 9.4% to $1.6 billion, and net income rising 11.1% to $1.2 billion. The nine-month diluted EPS reached $1.18, marking a 10.3% improvement from the previous year's $1.07.